Short interest for AtriCure gives investors a sense of the degree to which investors are betting on the decline of AtriCure's stock. Short interest data is updated every two weeks.

AtriCure Stock (NASDAQ:ATRC), Short Interest Report

AtriCure

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.

News

Price Target

Small Cap

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ATRC

COIN

INFA

INTR

TOST

WEST

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Coinbase To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Friday

New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market

Biotech

Penny Stocks

General

BSGM

Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies’ (NASDAQ: BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in Ne

ATXS

GKOS

MRNA

PGNY

ROIV

VTEX


	Morgan Stanley cut  VTEX  (NYSE: VTEX) price  target from $7 to $5.  Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on Friday.


Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday

AtriCure Inc

<p>Needham  analyst Mike Matson   maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and lowers the price target from $46 to $40.</p>


Needham Maintains Buy on AtriCure, Lowers Price Target to $40

Guidance

ArtiCure Sees FY24 Adj. EPS $(0.82)-$(0.74) Vs $(0.74) Est.; Revenue ~$459M-$466M Vs $461.304M Est.

<p>AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.23) by 8.7 percent. This is a 8.7 percent decrease over losses of $(0.23) per share from the same period last year.  The company reported quarterly sales of $108.851 million which beat the analyst consensus estimate of $106.902 million by 1.82 percent.  This is a 16.43 percent increase over sales of $93.494 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

AtriCure Q1 2024 Adj EPS $(0.25) Misses $(0.23) Estimate, Sales $108.851M Beat $106.902M Estimate

<p>Oppenheimer  analyst Suraj Kalia   upgrades AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) from Perform to Outperform and announces $32 price target.</p>


Upgrades

Oppenheimer Upgrades AtriCure to Outperform, Announces $32 Price Target

Health Care

AtriCure Launched cryoSPHERE+ Cryoablation Probe To Reduce Freeze Times By 25% Vs. AtriCure's Legacy cryoSPHERE Device. The Product Is Currently In An Extended Limited Launch Period In US, With Full Launch Expected By The End Of Q2

<p>In the preceding three months, 4 analysts have released ratings for AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for AtriCure, presenting an average target of $48.0, a high estimate of $58.00, and a low estimate of $42.00. This current average represents a 4.63% decrease from the previous average price target of $50.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1712750476_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive AtriCure. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$58.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$42.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$46.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to AtriCure. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of AtriCure compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of AtriCure's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of AtriCure's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ATRC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on AtriCure analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About AtriCure</h2>
<p>AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.</p>
<h3>A Deep Dive into AtriCure's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> AtriCure's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately <strong>21.03%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-9.19%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> AtriCure's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-2.11%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> AtriCure's ROA excels beyond industry benchmarks, reaching <strong>-1.61%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> AtriCure's debt-to-equity ratio is below the industry average at <strong>0.16</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Key Takeaways From AtriCure Analyst Ratings

<p>Needham  analyst Mike Matson   reiterates AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and maintains $46 price target.</p>


Reiteration

Needham Reiterates Buy on AtriCure, Maintains $46 Price Target

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.</p>
<ul>
<li>Piper Sandler raised the price target for <strong> Toast, Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tost#NYSE">TOST</a>) from $18 to $20. Piper Sandler analyst Clarke Jeffries maintained a Neutral rating. Toast shares fell 4.7% to close at $19.20 on Thursday. <a href="https://www.benzinga.com/quote/TOST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity boosted <strong> Coinbase Global, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coin#NASDAQ">COIN</a>) price target from $140 to $240. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Coinbase shares gained 3.3% to close at $165.67 on Thursday. <a href="https://www.benzinga.com/quote/COIN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham boosted the price target for <strong> AtriCure, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atrc#NASDAQ">ATRC</a>) from $44 to $46. Needham analyst Mike Matson maintained a Buy rating. AtriCure shares rose 5.1% to close at $34.21 on Thursday. <a href="https://www.benzinga.com/quote/ATRC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group raised <strong> Westrock Coffee Company </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/west#NASDAQ">WEST</a>) price target from $11 to $13. Telsey Advisory Group analyst Sarang Vora maintained an Outperform rating. Westrock Coffee shares gained 4% to close at $11.13 on Thursday. <a href="https://www.benzinga.com/quote/WEST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc increased the price target for <strong> IAC Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iac#NASDAQ">IAC</a>) from $70 to $72. Keybanc analyst Justin Patterson maintained an Overweight rating. IAC shares gained 3.2% to close at $55.77 on Thursday. <a href="https://www.benzinga.com/quote/IAC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs boosted the price target for <strong> Informatica Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/infa#NYSE">INFA</a>) from $26 to $44. Goldman Sachs analyst Kash Rangan upgraded the stock from Neutral to Buy. Informatica shares gained 12.7% to close at $33.97 on Thursday. <a href="https://www.benzinga.com/quote/INFA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup cut <strong> Inter &amp; Co, Inc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/intr#NASDAQ">INTR</a>) price target from $6.3 to $6. Citigroup analyst Rafael Frade downgraded the stock from Buy to Neutral. Inter shares fell 0.7% to close at $5.43 on Thursday. <a href="https://www.benzinga.com/quote/INTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen raised <strong> PVH Corp. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pvh#NYSE">PVH</a>) price target from $86 to $150. TD Cowen analyst John Kernan upgraded the stock from Market Perform to Outperform. PVH shares fell 0.3% to close at $128.08 on Thursday. <a href="https://www.benzinga.com/quote/PVH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Daiwa Capital boosted <strong> Arm Holdings plc </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arm#NASDAQ">ARM</a>) price target from $63 to $130. Daiwa Capital analyst Louis Miscioscia downgraded the stock from Buy to Neutral. Arm shares gained 5.8% to close at $133.68 on Thursday. <a href="https://www.benzinga.com/quote/ARM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised <strong> United Parcel Service, Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ups#NYSE">UPS</a>) price target from $165 to $170. Baird analyst Benjamin Hartford upgraded the stock from Neutral to Outperform. UPS shares rose 1.9% to close at $146.98 on Thursday. <a href="https://www.benzinga.com/quote/UPS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<p>&nbsp;</p>
<p>Check This Out: <a href="https://www.benzinga.com/news/earnings/24/02/37174587/coinbase-ppl-and-3-stocks-to-watch-heading-into-friday"><em> Coinbase, PPL And 3 Stocks To Watch Heading Into Friday </em></a></p>


<p>In the last three months, 4 analysts have published ratings on AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $49.75, a high estimate of $60.00, and a low estimate of $44.00. Witnessing a positive shift, the current average has risen by 6.99% from the previous average price target of $46.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1708084810_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of AtriCure by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$46.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Daniel Stauder</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$49.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AtriCure. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AtriCure compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of AtriCure's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of AtriCure's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ATRC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on AtriCure analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About AtriCure</h2>
<p>AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.</p>
<h3>AtriCure's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> AtriCure's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of <strong>18.07%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> AtriCure's net margin excels beyond industry benchmarks, reaching <strong>-9.21%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> AtriCure's ROE excels beyond industry benchmarks, reaching <strong>-1.96%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-1.52%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> AtriCure's debt-to-equity ratio is below the industry average at <strong>0.16</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Cracking The Code: Understanding Analyst Reviews For AtriCure

<p>Needham  analyst Mike Matson   maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and raises the price target from $44 to $46.</p>


Needham Maintains Buy on AtriCure, Raises Price Target to $46

<p><strong>AtriCure</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) reported its Q4 earnings results on Thursday, February 15, 2024 at 04:01 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>AtriCure beat estimated earnings by 8.7%, reporting an EPS of $-0.21 versus an estimate of $-0.23.</p>
<p>Revenue was up $18.52 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat on EPS by $0.11 which was followed by a 4.48% increase in the share price the next day.</p>
<p>Here's a look at AtriCure's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2023</strong></th>
<th><strong>Q2 2023</strong></th>
<th><strong>Q1 2023</strong></th>
<th><strong>Q4 2022</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.31</td>
<td>-0.29</td>
<td>-0.34</td>
<td>-0.18</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.20</td>
<td>-0.12</td>
<td>-0.23</td>
<td>-0.09</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>96.73M</td>
<td>97.49M</td>
<td>87.53M</td>
<td>87.66M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>98.29M</td>
<td>100.92M</td>
<td>93.49M</td>
<td>88.03M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for AtriCure <a href="https://www.benzinga.com/quote/ATRC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Recap: AtriCure Q4 Earnings

<p>AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.23) by 8.7 percent.  The company reported quarterly sales of $106.50 million which beat the analyst consensus estimate of $103.68 million by 2.72 percent.  This is a 20.98 percent increase over sales of $88.03 million the same period last year.</p>


AtriCure Q4 2023 Adj EPS $(0.21) Beats $(0.23) Estimate, Sales $106.50M Beat $103.68M Estimate

AGIO

ALKS

ALLT

ALNY

AMAT

AORT

APPN

ARCH

AUPH

BJRI

BLZE

BPMC

CBRE

CGNX

CLBT

CMBM

COHU

CORT

CRBG

CROX

CWST

DASH

DKNG

DNOW

EDRY

ELME

EPAM

GLOB

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HOUS

HTGC

IDCC

IRDM

IREN

IRWD

ITGR

JMIA

KELYA

KELYB

KNSL

LBTYA

LECO

Laboratory Corporation Of America Holdings

MERC

MTRN

MYTE

NSIT

NVMI

OPEN

ORAN

OTLY

PACB

PCOR

PDFS

PENN

PRAA

PRTA

RARE

RELX

ROKU

RPRX

Earnings Scheduled For February 15, 2024

<p><strong>AtriCure</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) is set to give its latest quarterly earnings report on Thursday, 2024-02-15. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that AtriCure will report an <strong>earnings per share</strong> (EPS) of $-0.23. </p>
<p>AtriCure bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.11, which was followed by a 4.48% increase in the share price the next day.</p>
<p>Here's a look at AtriCure's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2023</strong></th>
<th><strong>Q2 2023</strong></th>
<th><strong>Q1 2023</strong></th>
<th><strong>Q4 2022</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.31</td>
<td>-0.29</td>
<td>-0.34</td>
<td>-0.18</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.20</td>
<td>-0.12</td>
<td>-0.23</td>
<td>-0.09</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.48%</td>
<td>8.54%</td>
<td>9.99%</td>
<td>8.26%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1707922914_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of AtriCure were trading at $31.71 as of February 13. Over the last 52-week period, shares are down 21.4%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/ATRC/earnings"><strong>To track all earnings releases for AtriCure visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


AtriCure's Earnings: A Preview

<h3>Gainers</h3>
<ul>
<li><strong>Celularity</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares rose 43.4% to $0.27 during Thursday's pre-market session. The company's market cap stands at $52.3 million. </li>
<li><strong>Kronos Bio</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRON#NASDAQ">KRON</a>) stock moved upwards by 33.64% to $1.43. The company's market cap stands at $83.3 million. </li>
<li><strong>Jin Medical International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) shares rose 24.82% to $122.0. The market value of their outstanding shares is at $954.9 million. </li>
<li><strong>Telesis Bio</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) stock moved upwards by 20.33% to $0.38. The market value of their outstanding shares is at $11.3 million. </li>
<li><strong>Lipocine</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) shares increased by 18.7% to $4.57. The company's market cap stands at $24.2 million. </li>
<li><strong>Lucid Diagnostics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) stock rose 16.0% to $1.68. The market value of their outstanding shares is at $72.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Aravive</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAV#NASDAQ">ARAV</a>) stock fell 50.5% to $0.05 during Thursday's pre-market session. The company's market cap stands at $4.0 million. </li>
<li><strong>AtriCure</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) shares fell 34.16% to $22.0. The company's market cap stands at $1.0 billion. </li>
<li><strong>Processa Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares decreased by 18.29% to $0.22. The market value of their outstanding shares is at $5.4 million. </li>
<li><strong>Humana</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) stock declined by 14.24% to $384.0. The market value of their outstanding shares is at $47.2 billion. </li>
<li><strong>Mesoblast</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) stock fell 12.07% to $1.53. The market value of their outstanding shares is at $131.2 million. </li>
<li><strong>Adagene</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAG#NASDAQ">ADAG</a>) stock decreased by 9.76% to $3.61. The market value of their outstanding shares is at $158.2 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Movers

ADAG

ARAV

CELU

KRON

LPCN

LUCD

MESO

PCSA

TBIO

ZJYL

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<p>AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $52.0, with a high estimate of $60.00 and a low estimate of $44.00. Highlighting a 11.86% decrease, the current average has fallen from the previous average price target of $59.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1704369651_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of AtriCure by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Daniel Stauder</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$49.00</td>
<td>-</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$49.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Daniel Stauder</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$60.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AtriCure. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AtriCure compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of AtriCure's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ATRC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on AtriCure analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind AtriCure</h2>
<p>AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.</p>
<h3>AtriCure's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> AtriCure's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of <strong>18.07%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-9.21%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> AtriCure's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-1.96%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> AtriCure's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-1.52%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> AtriCure's debt-to-equity ratio is below the industry average at <strong>0.16</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


<p>Needham  analyst Mike Matson   maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and lowers the price target from $49 to $44.</p>


Needham Maintains Buy on AtriCure, Lowers Price Target to $44

<p>JMP Securities  analyst Daniel Stauder   reiterates AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Market Outperform and maintains $60 price target.</p>


JMP Securities Reiterates Market Outperform on AtriCure, Maintains $60 Price Target

<p>Within the last quarter, AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) has observed the following analyst ratings: </p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the last 3 months, 5 analysts have offered 12-month price targets for AtriCure. The company has an average price target of $52.8 with a high of $60.00 and a low of $49.00. </p>
<p>Below is a summary of how these 5 analysts rated AtriCure over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock</p>
<p><img src="https://www.benzinga.com/files/images/story/2023/1701259240_0.png" alt="price target chart" /></p>
<p>This current average represents a 17.5% decrease from the previous average price target of $64.00. </p>
<p><a href="https://www.benzinga.com/quote/ATRC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on AtriCure analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h1>Analyst Ratings: What Are They?</h1>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where AtriCure Stands With Analysts

<p>Needham  analyst Mike Matson   reiterates AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and maintains $49 price target.</p>


Needham Reiterates Buy on AtriCure, Maintains $49 Price Target

Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down

AtriCure upgraded at Oppenheimer on valuation

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Atricure (ATRC – Research Report), Alkermes (ALKS – ...

Analysts Are Bullish on These Healthcare Stocks: Atricure (ATRC), Alkermes (ALKS)

AtriCure Q1 2024 Earnings Preview

AtriCure Non-GAAP EPS of -$0.25 misses by $0.02, revenue of $108.9M beats by $2M

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>AtriCure</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/atrc-stock-quote/"><strong>ATRC</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>AtriCure reported earnings per share of -25 cents. This was below the analyst estimate for EPS of -23 cents.</li><li>The company reported revenue of $108.85 million.</li><li>This was 1.83% better than the analyst estimate for revenue of $106.90 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/atrc-stock-earnings-atricure-for-q1-of-2024/">ATRC Stock Earnings: AtriCure Misses EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ATRC Stock Earnings: AtriCure Misses EPS, Beats Revenue for Q1 2024

Analyst Daniel Stauder of JMP Securities reiterated a Buy rating on Atricure (ATRC – Research Report), retaining the price target of $60.00. Daniel...

AtriCure's Strong Growth and Market Position Justify Buy Rating

AtriCure, Inc. (ATRC) Q1 2024 Earnings Call Transcript

Analyst Michael Matson from Needham reiterated a Buy rating on Atricure (ATRC – Research Report) and decreased the price target to $40.00 from $46....

Atricure's Growth and Resilience Reinforce Buy Rating

Atricure (ATRC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Marie Thibault from BTI...

Atricure's Strong Performance and Growth Potential Affirm Buy Rating

ATEC

AZTA

CNMD

ENOV

IRTC

ISRG

KIDS

LIVN

NARI

RXST

SIBN

SRDX

VCYT

XRAY

Press Releases

AtriCure to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

AtriCure Appoints Shlomi Nachman to the Board of Directors

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2023, Provides Financial Outlook for 2024

AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference

AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results

AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference

AtriCure to Announce First Quarter 2024 Financial Results

AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management

AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference

-

-

-

-

-

-

-

-

-

-

-

-

-

-

AtriCure Stock (NASDAQ:ATRC), Short Interest Report

People Also Watch